Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 18Gastrointestinal 5Head & Neck 3Gynecologic 3Sarcoma 2Endocrine 2CNS 2Breast 2NET 1Myeloid 1Genitourinary 1Dermatologic 1

Conditions

Neuroendocrine Tumors 71Pheochromocytoma 8Gastro-enteropancreatic neuroendocrine tumor 8Paraganglioma 7Carcinoma, Neuroendocrine 7Carcinoid Tumor 7Adenoma, Islet Cell 7Sarcoma 5Pancreatic Neoplasms 5Neoplasms 5Melanoma 5Breast Neoplasms 5Thyroid Neoplasms 4Neuroblastoma 4Neoplasm Metastasis 4Mesothelioma 4Carcinoma, Merkel Cell 4Carcinoma 4Stomach Neoplasms 3Serotonin Syndrome 3Prostatic Neoplasms 3Ovarian Neoplasms 3Neuroectodermal Tumors, Primitive 3Meningioma 3Liver Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Central Nervous System Neoplasms 3Carcinoma, Non-Small-Cell Lung 3

Interventions

repotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Respiratory Tract Neoplasms × NET × 90 days × Clear all
NCT03093116 2026-05-27

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡